---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-018725"
form_type: "8-K"
ticker: "AVR"
cik: "0002011514"
company_name: "Anteris Technologies Global Corp."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T10:49:55.602169+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Anteris Q1 net loss $21.9M (up 36%); sales $0.6M (-27%); DurAVR IDE submitted

## Summary
- Net loss $21.9M vs $16.2M a year ago; revenue $0.6M down 27% on lower tissue demand.
- R&D spend $16.5M (+42%) driven by manufacturing scale-up ($3.5M) and PARADIGM trial prep ($1.5M).
- Cash at March 31: $49.0M; IPO green-shoe raised $0.47M; included in Russell 2000.
- DurAVR THV IDE for pivotal PARADIGM Trial submitted to FDA; 100+ patients treated; one-year data shows EOA 2.1 cm², MPG 8.6 mmHg, no valve mortality.
- Manufacturing capacity scaled to 3x 2024 levels; ADAPT tissue sourced from US and Australia to mitigate supply risk.

## SEC filing metadata
- accession: 0001140361-25-018725
- form_type: 8-K
- ticker: AVR
- cik: 0002011514
- company_name: Anteris Technologies Global Corp.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2011514/000114036125018725/0001140361-25-018725-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2011514/000114036125018725/ef20048845_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-018725
- JSON: https://secwatch.observer/filing/0001140361-25-018725.json
- Plain text: https://secwatch.observer/filing/0001140361-25-018725.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.